Chinese baby formula manufacturer Biostime International’s purchase of a majority stake in Australian health supplement maker Swisse Wellness sends a key message to the market - the acquisition of quality overseas assets isn't just for big state-owned players anymore.
Guangzhou-headquartered Biostime, which had a market value of $1.1 billion before the deal was announced, has taken a big bite by acquiring a controlling 83% interest in the unlisted vitamin maker for A$1.4 billion $992 million, equivalent to 22.5 times the target’s forecast earnings this year.
As the price tag values the Australian company at $1.2 billion, it means Biostime has effectively swallowed an entity that...
¬ Haymarket Media Limited. All rights reserved.
